ArticleBMC cancer2005
Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.
Article in BMC cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.Drugs · 2007Pooled it
- Regression of hepatic fibrosis in gamma-irradiated rats by mycophenolate mofetil: potential role of Egr-1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Relative carcinogenicity of tacrolimusWorld journal of hepatology · 2024Article
- Prostate Cancer in Transplant Receivers-A Narrative Review on Oncological Outcomes.Biomedicines · 2023Review
- The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro.Cancer immunology, immunotherapy : CII · 2021Article
- Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.Clinical kidney journal · 2018Article
- Mycophenolate Mofetil induces c-Jun-N-terminal kinase expression in 22Rv1 cells: an impact on androgen receptor signaling.Journal of Cancer · 2018Article
- Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.Journal of physiology and biochemistry · 2016Article
- Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.BMC cancer · 2016Article
- Downregulation of telomerase maintenance-relatedExperimental and therapeutic medicine · 2015Article
- Management and prevention of post-transplant malignancies in kidney transplant recipients.Clinical kidney journal · 2015Article
- Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.Pathology oncology research : POR · 2015Article
- Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis.World journal of hepatology · 2015Review
- Immunosuppressive drugs affect high-mannose/hybrid N-glycans on human allostimulated leukocytes.Analytical cellular pathology (Amsterdam) · 2015Article
- Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.PloS one · 2014Article
- Composite tissue allotransplantation immunology.Archives of plastic surgery · 2013Article
- Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid.International journal of clinical and experimental pathology · 2013Article
- Treating rheumatic patients with a malignancy.Arthritis research & therapy · 2011Review
- Effect of mycophenolate mofetil plus adriamycin on HepG-2 cells.World journal of hepatology · 2010Article
- Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.American journal of ophthalmology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor development remains one of the major obstacles following organ transplantation. Immunosuppressive drugs such as cyclosporine and tacrolimus directly contribute to enhanced malignancy, whereas the influence of the novel compound mycophenolate mofetil (MMF) on tumor cell dissemination has not been explored. We therefore investigated the adhesion capacity of colon, pancreas, prostate and kidney carcinoma cell lines to endothelium, as well as their beta1 integrin expression profile before and after MMF treatment.
methodsTumor cell adhesion to endothelial cell monolayers was evaluated in the presence of 0.1 and 1 microM MMF and compared to unstimulated controls. beta1 integrin analysis included alpha1beta1 (CD49a), alpha2beta1 (CD49b), alpha3beta1 (CD49c), alpha4beta1 (CD49d), alpha5beta1 (CD49e), and alpha6beta1 (CD49f) receptors, and was carried out by reverse transcriptase-polymerase chain reaction, confocal microscopy and flow cytometry.
resultsAdhesion of the colon carcinoma cell line HT-29 was strongly reduced in the presence of 0.1 muM MMF. This effect was accompanied by down-regulation of alpha3beta1 and alpha6beta1 surface expression and of alpha3beta1 and alpha6beta1 coding mRNA. Adhesion of the prostate tumor cell line DU-145 was blocked dose-dependently by MMF. In contrast to MMF's effects on HT-29 cells, MMF dose-dependently up-regulated alpha1beta1, alpha2beta1, alpha3beta1, and alpha5beta1 on DU-145 tumor cell membranes.
conclusionWe conclude that MMF possesses distinct anti-tumoral properties, particularly in colon and prostate carcinoma cells. Adhesion blockage of HT-29 cells was due to the loss of alpha3beta1 and alpha6beta1 surface expression, which might contribute to a reduced invasive behaviour of this tumor entity. The enhancement of integrin beta1 subtypes observed in DU-145 cells possibly causes re-differentiation towards a low-invasive phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.